1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Mineralys Eyes NDA As Lorundrostat Scores CKD Win In Race With AstraZeneca

Mineralys Is In A Close Race With AstraZeneca

 
• By Sushmita Panda

As it races AstraZeneca’s baxdrostat to market, Mineralys plans to file an NDA later this year, backed by strong efficacy and safety data across four trials.

Mineralys Therapeutics
Mineralys Therapeutics (Shutterstock)

Mineralys’s lorundrostat has demonstrated its potential to reduce blood pressure in patients with hypertension again, as the aldosterone synthase inhibitor has achieved a third clinical win in recent months giving close fight to AstraZeneca’s baxdrostat.

Key Takeaways
  • Lorundrostat met key efficacy and safety endpoints in the Phase II Explore-CKD trial, showing blood pressure and kidney benefits. 

      The biotech firm has announced positive topline data from its Phase II Explore-CKD trial evaluating the safety and efficacy of...

      More from Clinical Trials

      Novartis’s ‘Pipeline-In-A-Product’ Assets Progressing Well

       
      • By Kevin Grogan

      CMO Shreeram Aradhye talks to Scrip about the promise shown by ianalumab, remibrutinib and a next-generation CAR-T for immunological disorders.

      Vertex’s Pain Drug Failure Adds To Investor Doubts

       
      • By Andrew McConaghie

      A Phase II trial to develop a second NaV1.8 pain signal inhibitor for acute pain has failed and the US FDA has given a thumbs down on Journavx’s path to broader use in peripheral neuropathic pain.

      Cardiff Pushes Towards Colorectal Cancer Phase III As Funding Questions Loom

       
      • By Manas Mishra

      Cardiff Oncology is open to going it alone, a partnership and even an exit as the San Diego, CA-based firm tries to push its PLK1 inhibitor through late-stage development.

      Aurigene Oncology CEO On Biotech Valuations, CAR-Ts And Reimbursement Models

       
      • By Anju Ghangurde

      Aurigene Oncology CEO talks in this audio interview about the tough biotech funding environment, pipeline assets including a CAR-T therapy in Phase II, "hybrid" manufacturing, outcome-based reimbursement and the promise of bispecifics and multispecifics, including Akeso's PD-1/VEGF bispecific.

      More from Therapy Areas

      Vertex’s Pain Drug Failure Adds To Investor Doubts

       
      • By Andrew McConaghie

      A Phase II trial to develop a second NaV1.8 pain signal inhibitor for acute pain has failed and the US FDA has given a thumbs down on Journavx’s path to broader use in peripheral neuropathic pain.

      Cardiff Pushes Towards Colorectal Cancer Phase III As Funding Questions Loom

       
      • By Manas Mishra

      Cardiff Oncology is open to going it alone, a partnership and even an exit as the San Diego, CA-based firm tries to push its PLK1 inhibitor through late-stage development.

      Aurigene Oncology CEO On Biotech Valuations, CAR-Ts And Reimbursement Models

       
      • By Anju Ghangurde

      Aurigene Oncology CEO talks in this audio interview about the tough biotech funding environment, pipeline assets including a CAR-T therapy in Phase II, "hybrid" manufacturing, outcome-based reimbursement and the promise of bispecifics and multispecifics, including Akeso's PD-1/VEGF bispecific.